FINANCIAL RESULTS FULL YEAR 2024
May 19, 2025
FY 2024 AT A GLANCE
FINANCIAL REVIEW
OUTLOOK
Q&A
HIGHLIGHTS AND ACHIEVEMENTS
Progress in margins ahead of own expectations and strong cash flow dynamics despite challenging market environment
Pipeline progress
E.g. achievement of concluding development milestone for customer products in the field of transfusion diagnostics
New cooperations agreed
E.g. development cooperation in the field of immunodiagnostics aiming to rejuvenate an existing product (including additional functions)
Strengthening of local presence
Enhanced market position in Asia-Pacific and first sales synergies realized in the U.S. on the back of Natech acquisition
Dividend proposal of € 0.60 per share (€ 0.55 in the prior year)
FINANCIALS AT A GLANCE1
€ 000s | FY 2024 | FY 20232 | Change |
Sales | 257,624 | 270,414 | -4.7 % (cc: -4.9%) |
Adjusted EBITDA | 49,214 | 44,826 | +9.8% |
Adjusted EBITDA margin (%) | 19.1 | 16.6 +250 bps | |
Adjusted EBIT | 33,459 | 30,388 | +10.1% |
Adjusted EBIT margin (%) | 13.0 | 11.2 +180 bps | |
Adjusted consolidated net income | 20,496 | 19,009 | +7.8% |
Adjusted basic earnings per share (in €) | 1.69 | 1.56 | +8.3% |
Basic earnings per share IFRS (in €) | 1.32 | 1.26 | +4.8% |
bps = basis points
cc = at constant currency
1 For comparison purposes, adjusted figures have been adjusted to exclude amortization from purchase price allocations in the context of acquisitions, as well as for other one-off items (consulting and reorganization expenses in connection with M&A activities and one-off personnel expenses).
2 Restated in accordance with IAS 8.
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |